Mindera
Private Company
Funding information not available
Overview
Mindera Health, founded in 2019 and based in San Diego, is pioneering a novel diagnostic platform in dermatology. Its core technology, the Mind.Px™ patch, painlessly extracts RNA from the skin for transcriptomic analysis, aiming to replace subjective visual exams and invasive biopsies. The company is building the SkinAtlas™ dataset to power AI-driven analytics for skin diseases, with a validated initial application in guiding biologic selection for psoriasis, as demonstrated in a recent prospective clinical trial. Mindera positions its platform as a foundational tool for digital skin analytics across healthcare and consumer sectors.
Technology Platform
Proprietary dermal biomarker patch (Mind.Px™) for non-invasive RNA extraction from skin, combined with NGS and machine learning analytics to create predictive diagnostic tests. The platform is building the SkinAtlas™, a multi-modal skin data repository.
Opportunities
Risk Factors
Competitive Landscape
Mindera competes in the molecular dermatology diagnostics space. Direct competitors include companies developing genomic tests from skin biopsies (e.g., Castle Biosciences for cancer). It also faces competition from non-invasive imaging AI companies and the entrenched standard of care (visual exam/biopsy). Its unique painless patch and transcriptomic focus provide differentiation, but market education will be critical.